...
机译:Ibrutinib剂量粘附对先前处理过的CLL / SLL患者治疗疗效的影响
Univ Rochester Wilmot Canc Inst Rochester NY USA;
Dana Farber Canc Inst Boston MA 02115 USA;
Leeds Teaching Hosp St James Inst Oncol Leeds W Yorkshire England;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Hofstra Northwell Sch Med Hempstead NY USA;
Vanderbilt Ingram Canc Ctr Nashville TN USA;
Stanford Univ Stanford Canc Ctr Sch Med Stanford CA 94305 USA;
Royal North Shore Hosp Sydney NSW Australia;
Med Univ Vienna Div Hematol Dept Med 1 Vienna Austria;
New York Presbyterian Hosp Weill Cornell Med Coll New York NY USA;
Hop Avicenne Paris France;
Osped Niguarda Ca Granda Milan Italy;
Royal Marsden Hosp London England;
Med Univ Lodz Dept Hematol Lodz Poland;
Hosp Santa Creu St Pau Barcelona Spain;
Swedish Canc Inst Seattle WA USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
AbbVie Pharmacycl LLC Sunnyvale CA USA;
AbbVie Pharmacycl LLC Sunnyvale CA USA;
AbbVie Pharmacycl LLC Sunnyvale CA USA;
AbbVie Pharmacycl LLC Sunnyvale CA USA;
Ohio State Univ Med Ctr Columbus OH 43210 USA;
机译:Ibrutinib剂量粘附对先前处理过的CLL / SLL患者治疗疗效的影响
机译:CLL / SLL患者的一线Ibrutinib治疗的长期疗效和安全性:从第3期的5年后续转发-2研究
机译:依鲁替尼在患有复发性/难治性(R / R)慢性淋巴细胞性白血病(CLL)/小淋巴细胞性淋巴瘤(SLL)的患者中的安全性和有效性。进行过的同种异体干细胞移植
机译:“ Pi(脾)的调节和心(心)的保护”法治疗冠心病的冠心病治疗方案前瞻性临床队列研究
机译:成本分享对弥漫性大B细胞淋巴瘤患者依赖于伊布洛尼布的影响
机译:依鲁替尼剂量依从性对先前接受过CLL / SLL治疗的患者的疗效的影响
机译:教师意见建议,对CLL / SLL患者的一线Ibrutinib治疗的长期疗效和安全性:从第3期的5年后续进行共振-2研究。